{"abstract":"The National Cancer Institute, National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to Selecta Biosciences (\"Selecta\") located in Watertown, Massachusetts to practice the inventions embodied in the patent applications listed in the Supplementary Information section of this notice.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2017/02/27/2017-03823.html","cfr_references":[],"citation":"82 FR 11926","comment_url":null,"comments_close_on":"2017-03-14","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the NCI Technology Transfer Center on or before March 14, 2017 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2017-03823","effective_on":null,"end_page":11927,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2017/02/27/2017-03823.xml","html_url":"https://www.federalregister.gov/documents/2017/02/27/2017-03823/prospective-grant-of-exclusive-patent-license-the-development-of-an-anti-mesothelin-recombinant","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2017-03823?publication_date=2017-02-27","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2017-02-27/2017-03823/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":187,"last_updated":"2026-06-23 22:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2017-02-27/pdf/2017-03823.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2017-03823.pdf?1487943993","publication_date":"2017-02-27","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2017/02/27/2017-03823.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-03-01T00:21:54Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":11926,"subtype":null,"title":"Prospective Grant of Exclusive Patent License: The Development of an Anti-Mesothelin Recombinant Immunotoxin (RIT) for the Treatment of Human Cancers.","toc_doc":"Development of an Anti-mesothelin Recombinant Immunotoxin (RIT) for the Treatment of Human Cancers","toc_subject":"Exclusive Patent Licenses; Proposed Approvals:","topics":[],"type":"Notice","volume":82}